Response to BRAF and MEK1/2 inhibition in a young adult with BRAF V600E mutant epithelioid glioblastoma multiforme: A Case Report and Literature Review

Louis, 2016, The 2016 World Health Organization classification of tumors of the central nervous system: a summary, Acta Neuropathologica, 131, 803, 10.1007/s00401-016-1545-1 Broniscer, 2014, Clinical, radiological, histological and molecular characteristics of paediatric epithelioid glioblastoma, Neuropathol Appl Neurobiol, 40, 327, 10.1111/nan.12093 Sugimoto, 2016, Epithelioid/rhabdoid glioblastoma: a highly aggressive subtype of glioblastoma, Brain Tumor Pathol, 33, 137, 10.1007/s10014-015-0243-3 Huang, 2019, The radiological imaging features of easily misdiagnosed epithelioid glioblastoma in seven patients, World Neurosurg, 124, 527, 10.1016/j.wneu.2018.12.128 Gokden, 2017, If it is not a glioblastoma, then what is it? A differential diagnostic review, Adv Anat Pathol, 24, 379, 10.1097/PAP.0000000000000170 Stupp, 2005, Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma, N Engl J Med, 352, 987, 10.1056/NEJMoa043330 Brandes, 1996, The role of chemotherapy in recurrent malignant gliomas: an overview, Cancer Invest, 14, 551, 10.3109/07357909609076900 Kleinschmidt-DeMasters, 2013, Epithelioid GBMs show a high percentage of BRAF V600E mutation, Am J Surg Pathol, 37, 685, 10.1097/PAS.0b013e31827f9c5e Robert, 2015, Improved overall survival in melanoma with combined dabrafenib and trametinib, N Engl J Med, 372, 30, 10.1056/NEJMoa1412690 Larkin, 2014, Combined vemurafenib and cobimetinib in BRAF-mutated melanoma, N Engl J Med, 371, 1867, 10.1056/NEJMoa1408868 Planchard, 2017, Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial, Lancet Oncol, 18, 1307, 10.1016/S1470-2045(17)30679-4 Corcoran, 2015, Combined BRAF and MEK inhibition with dabrafenib and trametinib in BRAF V600-mutant colorectal cancer, J Clin Oncol, 33, 4023, 10.1200/JCO.2015.63.2471 Subbiah, 2020, Pan-cancer efficacy of vemurafenib in BRAF V600 -mutant non-melanoma cancers, Cancer Discov, 10, 657, 10.1158/2159-8290.CD-19-1265 Wen, 2019, ACTR-30. updated efficacy and safety of dabrafenib plus trametinib in patients with recurrent/refractory BRAF V600E–mutated high-grade glioma (HGG) and low-grade glioma (LGG), Neuro Oncol, 21, vi19, 10.1093/neuonc/noz175.073 Finneran, 2019, Epithelioid glioblastoma presenting as aphasia in a young adult with ovarian cancer: a case report, Clin Case Rep, 7, 821, 10.1002/ccr3.2088 Korshunov, 2018, Epithelioid glioblastomas stratify into established diagnostic subsets upon integrated molecular analysis, Brain Pathol, 28, 656, 10.1111/bpa.12566 Alexandrescu, 2016, Epithelioid glioblastomas and anaplastic epithelioid pleomorphic xanthoastrocytomas–same entity or first cousins?, Brain Pathol, 26, 215, 10.1111/bpa.12295 Schindler, 2011, Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma, Acta Neuropathol, 121, 397, 10.1007/s00401-011-0802-6 Maraka, 2018, BRAF alterations in primary brain tumors, Discovery Med, 26, 51 Wan, 2004, Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF, Cell, 116, 855, 10.1016/S0092-8674(04)00215-6 Chapman, 2011, Improved survival with vemurafenib in melanoma with BRAF V600E mutation, N Engl J Med, 364, 2507, 10.1056/NEJMoa1103782 Hauschild, 2012, Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial, The Lancet, 380, 358, 10.1016/S0140-6736(12)60868-X Mittapalli, 2013, Mechanisms limiting distribution of the threonine-protein kinase B-RaF(V600E) inhibitor dabrafenib to the brain: implications for the treatment of melanoma brain metastases, J Pharmacol Exp Ther, 344, 655, 10.1124/jpet.112.201475 Spain, 2016, The combination of vemurafenib and cobimetinib in advanced melanoma, Expert Opin Orphan Drugs, 4, 1105, 10.1080/21678707.2016.1241707 Kushnirsky, 2020, Prolonged complete response with combined dabrafenib and trametinib after BRAF inhibitor failure in BRAF-mutant glioblastoma, JCO Precis Oncol, 4, 44, 10.1200/PO.19.00272 Woo, 2019, Regression of BRAFV600E mutant adult glioblastoma after primary combined BRAF-MEK inhibitor targeted therapy: a report of two cases, Oncotarget, 10, 3818, 10.18632/oncotarget.26932 Robinson, 2014, Complete clinical regression of a BRAF V600E-mutant pediatric glioblastoma multiforme after BRAF inhibitor therapy, BMC Cancer, 14, 258, 10.1186/1471-2407-14-258 Burger, 2017, Dabrafenib in patients with recurrent, BRAF V600E mutated malignant glioma and leptomeningeal disease, Oncol Rep, 38, 3291 Ceccon, 2018, Dabrafenib treatment in a patient with an epithelioid glioblastoma and BRAF V600E mutation, Int J Mol Sci, 19, 10.3390/ijms19041090 Arvanitis, 2014, NT-03dramatic response induced by vemurafenib in a BRAF V600E-mutated bevacizumab refractory glioblastoma, Neuro Oncol, 16, v159, 10.1093/neuonc/nou265.3 Beba Abadal, 2017, Eleven month progression–free survival on vemurafenib monotherapy in a patient with recurrent and metastatic BRAF V600E–mutated glioblastoma WHO grade 4, JCO Precis Oncol, 1 Leaver, 2016, Response of metastatic glioma to vemurafenib, Neuro-Oncol Pract, 3, 268, 10.1093/nop/npv054